These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 36376274)
1. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells. Chu YD; Fan TC; Lai MW; Yeh CT Cell Death Dis; 2022 Nov; 13(11):956. PubMed ID: 36376274 [TBL] [Abstract][Full Text] [Related]
2. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683 [TBL] [Abstract][Full Text] [Related]
3. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726 [TBL] [Abstract][Full Text] [Related]
4. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947 [TBL] [Abstract][Full Text] [Related]
5. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Liang KH; Lin CL; Chen SF; Chiu CW; Yang PC; Chang ML; Lin CC; Sung KF; Yeh C; Hung CF; Chien RN; Yeh CT Pharmacogenomics; 2016 Mar; 17(4):353-66. PubMed ID: 26871639 [TBL] [Abstract][Full Text] [Related]
6. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Lin CC; Hsu CW; Chen YC; Chang ML; Liang KH; Lai MW; Lin CL; Chien RN; Lin KH; Yeh CT Pharmacogenomics J; 2020 Feb; 20(1):57-68. PubMed ID: 31611591 [TBL] [Abstract][Full Text] [Related]
7. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Liang KH; Lin CC; Yeh CT Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146 [TBL] [Abstract][Full Text] [Related]
8. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Chen WT; Lin SM; Lee WC; Wu TJ; Lin CC; Shen CH; Chang ML; Lin CL; Yeh CT Hepatol Int; 2022 Feb; 16(1):148-158. PubMed ID: 34982369 [TBL] [Abstract][Full Text] [Related]
9. GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. Lin WR; Yeh CT Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098271 [TBL] [Abstract][Full Text] [Related]
10. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048 [TBL] [Abstract][Full Text] [Related]
11. Association of rs9679162 Genetic Polymorphism and Aberrant Expression of Polypeptide Lin NC; Shih YH; Chiu KC; Li PJ; Yang HW; Lan WC; Hsia SM; Wang TH; Shieh TM Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077753 [TBL] [Abstract][Full Text] [Related]
16. The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. Wang R; Yu C; Zhao D; Wu M; Yang Z Oncol Rep; 2013 Aug; 30(2):667-76. PubMed ID: 23708057 [TBL] [Abstract][Full Text] [Related]
17. GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway. Li HW; Liu MB; Jiang X; Song T; Feng SX; Wu JY; Deng PF; Wang XY Future Oncol; 2022 Jan; 18(2):149-161. PubMed ID: 34643088 [No Abstract] [Full Text] [Related]
18. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321 [TBL] [Abstract][Full Text] [Related]
19. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling. Huang MJ; Hu RH; Chou CH; Hsu CL; Liu YW; Huang J; Hung JS; Lai IR; Juan HF; Yu SL; Wu YM; Huang MC Oncotarget; 2015 Mar; 6(8):5650-65. PubMed ID: 25730904 [TBL] [Abstract][Full Text] [Related]
20. GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment. Song KH; Park MS; Nandu TS; Gadad S; Kim SC; Kim MY Nat Commun; 2016 Dec; 7():13796. PubMed ID: 27982029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]